Canine Parainfluenza Virus

Overview and Taxonomy of Canine Parainfluenza Virus

Canine parainfluenza virus (CPIV) represents one of the most significant viral contributors to the canine infectious respiratory disease complex (CIRDC), a multifactorial syndrome that imposes a substantial clinical and economic burden on canine populations worldwide. The virus is a primary etiological agent of infectious tracheobronchitis, colloquially known as "kennel cough," a condition characterized by an acute-onset, highly transmissible paroxysmal cough that can persist for weeks. Beyond its role as a standalone pathogen, CPIV is frequently implicated in polymicrobial infections, often acting synergistically with bacterial agents such as Bordetella bronchiseptica and Mycoplasma spp. to exacerbate clinical severity and prolong disease duration [2, 9, 13, 17]. Understanding the taxonomic position, genomic architecture, and biological properties of CPIV is foundational to appreciating its pathogenesis, its epidemiological dynamics, and the rationale behind current diagnostic and prophylactic strategies.

Taxonomic Classification and Nomenclature

CPIV is a negative-sense, single-stranded RNA virus classified within the family Paramyxoviridae, subfamily Rubulavirinae, genus Orthorubulavirus. The virus has undergone several nomenclatural revisions over the decades, reflecting advances in molecular characterization and a clearer understanding of its host range and antigenic relationships. Originally designated simian virus 5 (SV5) following its initial isolation from primary monkey kidney cell cultures, the virus was later referred to as parainfluenza virus 5 (PIV5) to reflect its antigenic relatedness to the human parainfluenza viruses. In the veterinary field, it has been historically and commonly termed canine parainfluenza virus (CPIV) or, more specifically, canine parainfluenza virus type 2 (CPiV-2) to distinguish it from other paramyxoviruses [10, 15]. The most recent taxonomic revision by the International Committee on Taxonomy of Viruses (ICTV) has assigned the species name Orthorubulavirus mammalis, a designation that acknowledges its broad mammalian host range and its placement within the rubulavirus genus [5, 11]. It is critical for researchers and clinicians to recognize that CPIV, PIV5, and SV5 refer to the same virus, a point of confusion that has historically complicated the interpretation of epidemiological and experimental data. The virus is not a true "influenza" virus, nor is it closely related antigenically to the human parainfluenza viruses (HPIV-1 through HPIV-4), despite the shared "parainfluenza" moniker. Instead, its closest relatives within the Orthorubulavirus genus include mumps virus and human parainfluenza virus type 2 (HPIV-2), reflecting a distinct evolutionary lineage [4, 10].

Genomic Organization and Virion Structure

The CPIV genome is approximately 15,246 nucleotides in length and is organized into seven non-overlapping genes in the order 3′-NP-V/P-M-F-SH-HN-L-5′, encoding a total of eight known proteins [8, 11]. This compact genome is encapsidated by the nucleocapsid protein (NP) to form a helical ribonucleoprotein complex, which serves as the template for transcription and replication. The virion itself is pleomorphic, typically spherical, and enveloped, with surface glycoprotein spikes composed of the hemagglutinin-neuraminidase (HN) and fusion (F) proteins. The HN protein mediates viral attachment to sialic acid-containing receptors on host cells and possesses neuraminidase activity, which facilitates viral release from infected cells. The F protein drives the pH-independent fusion of the viral envelope with the host cell membrane at the cell surface, a hallmark of paramyxovirus entry [10]. Beneath the envelope lies the matrix (M) protein, which orchestrates virion assembly and budding. The small hydrophobic (SH) protein is a transmembrane protein of uncertain function; intriguingly, some canine and porcine isolates carry mutations in the SH gene that abrogate its expression, suggesting that this protein may be dispensable for replication in certain hosts or that its loss may confer a selective advantage in these species [15]. The large (L) protein, in complex with the phosphoprotein (P), constitutes the viral RNA-dependent RNA polymerase, responsible for both transcription of mRNA and replication of the full-length genome [3, 8].

The V Protein: A Multifunctional Nonstructural Protein

Among the most biologically intriguing features of CPIV is its V protein, a nonstructural protein expressed from a dedicated open reading frame (ORF) within the P/V gene through a process of transcriptional editing [4]. The V protein is a quintessential paramyxoviral accessory protein, and CPIV V is particularly well-studied for its pleiotropic roles in subverting host antiviral defenses. The V protein acts as a potent antagonist of the type I interferon (IFN) response, primarily through its ability to bind and degrade STAT1 (signal transducer and activator of transcription 1), a key component of the JAK-STAT signaling pathway that is critical for interferon-stimulated gene (ISG) expression. By inhibiting the interferon response, the V protein creates a permissive environment for viral replication [4]. Additionally, the V protein has been shown to modulate the host cell cycle, inhibit apoptosis (thereby prolonging the survival of infected cells to maximize viral progeny production), and may interfere with other innate immune pathways. The multifunctional nature of the V protein has also attracted interest beyond virology; researchers are actively exploring its potential as a platform for oncolytic virus therapy and as a component of self-amplifying RNA vaccine vectors, capitalizing on its ability to modulate host cell biology in a controlled manner [4].

Genomic Stability and Evolutionary Implications

A remarkable and somewhat paradoxical feature of CPIV is its extraordinary genetic stability. Comparative genomic analyses of strains isolated from humans, dogs, pigs, and monkeys over a span of more than four decades have revealed that the virus exhibits an average pairwise nucleotide difference of only 2.1% across the entire genome, with only 7.8% of nucleotide positions displaying any variability [15]. This degree of conservation is unusually low for an RNA virus, which typically accumulates mutations at a high rate due to the error-prone nature of RNA-dependent RNA polymerases. The stability is so pronounced that deep sequencing of laboratory-passaged strains revealed virtually no accumulation of mutations even under conditions of high multiplicities of infection and competition with defective interfering genomes [15]. This genetic stasis has profound implications: it suggests that CPIV is under strong purifying selection, that its antigenic sites (particularly on the HN protein) are not subject to the same degree of immune-driven variation seen in viruses like influenza, and that existing vaccines based on older strains are likely to remain effective against contemporary circulating field strains. The lack of convincing evidence for antigenic drift in the HN gene supports the feasibility of long-term vaccine efficacy and underscores the potential of CPIV as a stable viral vector for heterologous antigen delivery [10, 15].

Host Range and Zoonotic Potential

Historically, CPIV has been considered a virus of canids, with dogs serving as the primary clinical host. However, the virus has a remarkably broad host range in nature, having been isolated from or serologically detected in a wide array of mammalian species, including humans, non-human primates (macaques), swine, cats, ferrets, and even lesser pandas [11, 15]. The detection of CPIV in a lesser panda with respiratory disease in a Chinese zoo highlights the potential for interspecies transmission and raises questions about the role of wildlife as reservoirs [11]. Despite its extensive host range, CPIV is not currently classified as a significant zoonotic pathogen by the World Health Organization (WHO) or the World Organisation for Animal Health (WOAH). Neutralizing antibodies against PIV5 have been detected in roughly 29% of human serum samples, indicating that human exposure is not uncommon [16]. Importantly, however, a causal link between CPIV infection and clinical disease in immunocompetent humans has not been established; infections in humans are typically subclinical or asymptomatic. This distinction is critical for public health risk communication. The virus is not considered a threat to human health, and it is not classified as a notifiable disease by WOAH. Nevertheless, its ability to replicate in human cells in vitro and the presence of antibodies in human populations warrant continued surveillance, particularly as CPIV-based vaccine vectors advance toward clinical trials for human use [10, 16].

The Role of CPIV in Canine Infectious Respiratory Disease Complex

Within the CIRDC, CPIV is one of the most consistently and frequently identified viral agents. Large-scale epidemiological studies from diverse geographic regions, including the United States, Europe, and Asia, consistently report CPIV detection rates ranging from approximately 5% to 20% in canine populations, with higher prevalence observed in congregate settings such as shelters, boarding kennels, and veterinary hospitals [2, 12-14, 17]. A five-year retrospective analysis of diagnostic submissions from a veterinary laboratory in Georgia, USA, identified CPIV as the single most prevalent viral pathogen, detected in 16% of all CIRDC cases, surpassing canine respiratory coronavirus (7%) and canine adenovirus type 2 (4%) [2]. Similarly, a comprehensive review of European CIRDC epidemiology emphasized that CPIV remains an important primary pathogen that facilitates co-infection with other viral and bacterial agents, thereby contributing disproportionately to the overall morbidity associated with the syndrome [17]. The virus is capable of causing clinical disease as a sole infectious agent, as demonstrated in a well-documented case of a vaccinated household dog presenting with acute dry cough and diffuse interstitial lung infiltrates, in which only CPIV was detected by molecular diagnostics [6]. However, the most severe clinical manifestations, including mucopurulent nasal discharge, productive cough, and bronchopneumonia, are typically observed when CPIV is part of a polymicrobial infection, particularly with Bordetella bronchiseptica or Mycoplasma cynos [9, 18]. The virus is shed in high concentrations in respiratory secretions, and transmission occurs via direct contact with contaminated fomites or aerosolized droplets. Importantly, subclinically infected dogs can shed CPIV for extended periods, serving as insidious reservoirs that perpetuate viral circulation within susceptible populations [1, 7]. This subclinical shedding has been confirmed in recent studies from Iraq, where CPIV was detected in 34% of apparently healthy dogs, underscoring the challenge of controlling the virus in environments where rigorous biosecurity cannot be maintained [1].

Molecular Pathogenesis and Replication Mechanism

Canine parainfluenza virus (CPIV), classified as Orthorubulavirus mammalis (formerly simian virus 5 or parainfluenza virus 5), is a negative-sense, nonsegmented, single-stranded RNA virus belonging to the family Paramyxoviridae, subfamily Rubulavirinae [4, 10]. Its molecular pathogenesis is intimately linked to its genomic architecture, replication strategy, and a sophisticated arsenal of nonstructural proteins that subvert host antiviral defenses. Understanding these mechanisms at the molecular level is essential for elucidating how CPIV establishes infection in the canine respiratory tract, persists in populations, and contributes to the canine infectious respiratory disease complex (CIRDC). The virus is of significant concern to the World Organisation for Animal Health (WOAH) due to its role in kennel cough and its potential for interspecies transmission.

Genomic Organization and Virion Structure

The CPIV genome is approximately 15,246 nucleotides in length and exhibits a remarkably conserved organization across isolates from diverse hosts and geographic origins [8, 11, 15]. The genome consists of seven non-overlapping genes arranged in the conserved paramyxovirus order: 3′-NP-P/V-M-F-SH-HN-L-5′. This gene order encodes eight known proteins: the nucleocapsid protein (NP), the phosphoprotein (P), the V protein (an accessory protein derived from the P gene via RNA editing), the matrix protein (M), the fusion glycoprotein (F), the small hydrophobic protein (SH), the hemagglutinin-neuraminidase glycoprotein (HN), and the large RNA-dependent RNA polymerase protein (L) [8, 11]. Each protein is flanked by conserved gene-start and gene-end signals critical for transcriptional initiation and polyadenylation.

The virion is pleomorphic, spherical to filamentous, and enveloped. The helical nucleocapsid consists of genomic RNA tightly associated with NP, P, and L, forming the minimal replicative unit. The M protein lines the inner leaflet of the lipid envelope, providing structural integrity and coordinating assembly. The two surface glycoproteins, HN and F, project from the envelope as spike-like structures. HN mediates receptor attachment and possesses neuraminidase activity, while F drives fusion of the viral envelope with the host cell membrane at neutral pH, a hallmark of paramyxovirus entry. The SH protein, a small transmembrane protein, is not essential for replication in many cell lines but plays a critical role in blocking apoptosis and modulating the host inflammatory response [15]. The V protein, a nonstructural component, is a multifunctional virulence factor that targets the host interferon (IFN) system [4].

Viral Attachment and Entry

CPIV entry into susceptible host cells is a multistep process initiated by the binding of the HN glycoprotein to sialic acid-containing receptors on the surface of target cells, primarily ciliated respiratory epithelial cells. HN recognizes α-2,3- and α-2,6-linked sialic acids, a broad receptor specificity that facilitates infection of a wide range of mammalian cell types, including Madin-Darby canine kidney (MDCK) cells and Vero cells [8, 25]. While the receptor distribution on canine respiratory epithelium favors infection of the upper and lower airways, the virus can also infect macrophages and other cell types, contributing to systemic dissemination in rare cases.

Following receptor binding, HN undergoes a conformational change that activates the F protein. This activation, requiring the close apposition of HN and F in the viral envelope, triggers F to insert its hydrophobic fusion peptide into the host cell membrane. Subsequent refolding of F into a six-helix bundle brings the viral and cellular membranes into close proximity, culminating in fusion and the release of the viral ribonucleocapsid (RNP) into the cytoplasm [10]. Entry is pH-independent and occurs directly at the plasma membrane, a characteristic of most paramyxoviruses. The stability of the F protein and its efficient triggering by HN are crucial for CPIV's high infectivity in vitro, allowing it to grow to high titers in many cell types [10].

Transcription and Genome Replication

Once the RNP is released into the cytoplasm, the viral polymerase complex (L-P) initiates transcription from the 3′ end of the genome. Transcription follows a stop-start model governed by conserved gene-end and gene-start sequences. The polymerase enters at the 3′ leader region and transcribes successive genes, with a defined gradient of transcription: genes closer to the 3′ end (NP, P/V) are transcribed more abundantly than those at the 5′ end (L) [8]. This gradient is a conserved regulatory mechanism in paramyxoviruses, ensuring that structural proteins required in large quantities (e.g., NP) are produced in excess of the catalytic polymerase components.

The P gene of CPIV is unique in that it produces multiple mRNA species through a co-transcriptional RNA editing mechanism. The polymerase stutters at a specific editing site (a run of G residues), inserting one or two nontemplated G residues into a fraction of the P gene transcripts. This insertion shifts the reading frame, generating the V protein (with one G insertion) and, in some rubulaviruses, the W or I proteins [4]. The V protein shares its N-terminal domain with P but possesses a unique zinc-binding C-terminal domain that is central to its immune evasion functions. This editing strategy allows CPIV to maximize the coding capacity of its compact genome and to fine-tune the balance between viral replication and host antagonism.

Genome replication, in contrast to transcription, requires a switch to a read-through mode where the polymerase ignores the gene-end signals and synthesizes a full-length, positive-sense antigenome. The antigenome serves as a template for the production of progeny negative-sense genomes. The switch from transcription to replication is regulated by the intracellular concentration of the NP protein, which is necessary to encapsidate nascent RNA chains. Once sufficient NP is available, the polymerase becomes processive, generating full-length antigenomic and genomic RNAs that are immediately encapsidated by NP.

Assembly and Budding

Assembly of progeny virions occurs at the plasma membrane. The M protein orchestrates this process by binding to the cytoplasmic tails of the HN and F glycoproteins, which have trafficked to the host cell membrane via the secretory pathway. The M protein also interacts with the RNP, condensing it into a helical structure and linking it to the budding site. The SH protein, though nonessential for replication in many continuous cell lines, is proposed to facilitate budding by influencing membrane curvature and by blocking apoptosis, thereby prolonging the window for virion production [4, 15].

Budding of CPIV is mediated by the M protein's ability to recruit the host ESCRT (endosomal sorting complexes required for transport) machinery. This interaction, often through late domains (e.g., PPxY or PTAP motifs) in the M protein, drives membrane scission and release of the enveloped particle. Interestingly, some canine and porcine CPIV isolates have been found to encode a truncated, nonfunctional SH protein, suggesting that SH is dispensable for replication in dogs and may indicate that the canine host is not the natural reservoir for CPIV [15]. This finding has important implications for understanding the evolutionary history and host range of the virus.

Molecular Mechanisms of Pathogenesis

The molecular pathogenesis of CPIV is a consequence of its cytolytic replication cycle, its capacity to evade the innate immune response, and its synergistic interactions with other CIRDC pathogens. The primary target cells are ciliated epithelial cells lining the nasal passages, trachea, bronchi, and bronchioles. Infection leads to ciliary stasis, loss of ciliated cells, and disruption of the mucociliary escalator, a critical first-line mechanical defense [9, 22]. This damage predisposes the host to secondary bacterial colonization, particularly by Bordetella bronchiseptica and Mycoplasma cynos, a phenomenon well documented in experimental co-infection models [9, 12, 18]. The combination of CPIV and B. bronchiseptica results in more severe clinical signs, including pronounced purulent tracheobronchitis and bronchopneumonia, compared to infection with either agent alone [9].

A key component of CPIV pathogenesis is the V protein. The CPIV V protein is a potent antagonist of the host interferon (IFN) response, acting at multiple levels [4]. The C-terminal domain of V binds to the cytoplasmic pattern recognition receptors MDA5 and RIG-I, inhibiting their ability to activate the downstream signaling cascade that leads to IFN-β induction. Furthermore, V targets the STAT family of transcription factors, specifically STAT1 and STAT2, by promoting their proteasomal degradation or by blocking their nuclear translocation. This effectively cripples the type I IFN signaling pathway, preventing the establishment of an antiviral state in infected and neighboring cells. By blocking apoptosis and altering the host cell cycle, the V protein also provides the virus with a prolonged replication window [4].

The SH protein also contributes to pathogenesis by inhibiting the tumor necrosis factor alpha (TNF-α) signaling pathway and blocking apoptosis. By preventing premature cell death, SH ensures that infected cells remain viable long enough to support robust viral replication and progeny release [4]. The high genetic stability of the CPIV genome, as demonstrated by deep sequencing of isolates from different hosts and geographic regions spanning decades, suggests a highly adapted molecular machinery with little need for antigenic drift to maintain fitness [15]. However, the emergence of distinct phylogenetic clades, particularly in the F gene, has been correlated with reduced vaccine efficacy in some regions, highlighting the potential for antigenic variation to impact protection [14].

Role of Co-Infections and Host Factors

The molecular pathogenesis of CPIV is rarely an isolated event in clinical cases. Epidemiological data consistently demonstrate that CPIV is frequently detected as a co-pathogen, most commonly with Mycoplasma cynos and Bordetella bronchiseptica [2, 12, 13, 18]. Co-infection with canine distemper virus (CDV) has also been documented [19]. The synergistic interaction between CPIV and bacteria can be explained by the virus-induced damage to the respiratory epithelium, which exposes basement membrane components and facilitates bacterial adherence. Additionally, the immunosuppressive effects of the V protein may dampen the host's ability to mount an effective antibacterial response, creating a permissive environment for opportunistic bacterial overgrowth.

Host factors, particularly age and vaccination status, profoundly influence the outcome of CPIV infection. Serological surveys have shown that seropositivity rates for CPIV increase with age, reflecting cumulative exposure, while maternal antibodies in young puppies can interfere with the efficacy of early-life vaccination [20, 24]. The presence of neutralizing antibodies is strongly associated with reduced viral shedding and milder clinical signs, but sterilizing immunity is rarely achieved [21, 23]. Even vaccinated dogs can become infected and shed virus, underscoring the importance of herd immunity and the limitations of current vaccine formulations [17, 21].

Epidemiological Profile and Reservoir Dynamics

The epidemiological landscape of Canine Parainfluenza Virus (CPIV) is defined by its ubiquitous presence across global canine populations, its capacity for sustained subclinical circulation, and a complex interplay of host and environmental factors that govern transmission dynamics. As a core constituent of the Canine Infectious Respiratory Disease Complex (CIRDC), CPIV demonstrates a prevalence pattern that is both geographically consistent and temporally dynamic, with evidence increasingly pointing toward the critical role of asymptomatic carriers in maintaining viral circulation and driving outbreaks in high-density dog populations.

Global Prevalence and Geographic Distribution

Systematic surveillance across multiple continents reveals that CPIV is among the most frequently detected viral pathogens in canine respiratory disease, with prevalence rates varying markedly according to sampling population, diagnostic methodology, and geographic region. A comprehensive five-year retrospective analysis of 459 cases submitted to a veterinary diagnostic laboratory in Georgia, USA, from 2018 to 2022 identified CPIV as the predominant viral agent, detected in 16% of all cases, far exceeding the prevalence of canine adenovirus type 2 (CAV-2) at 4%, canine distemper virus (CDV) at 3%, canine respiratory coronavirus (CRCoV) at 7%, and canine influenza virus (CIV) at 2% [2]. This predominance is corroborated by a large-scale European review encompassing 68 peer-reviewed publications from 1965 to 2025, which identified CPIV and CRCoV as the most frequently reported viral agents across the continent, with co-infection rates being notably high [13]. In a retrospective analysis of 705 canine respiratory PCR panels performed at the New York State Animal Health Diagnostic Center during 2023, Mycoplasma cynos was the most common pathogen (66%), yet CPIV remained the most frequently identified viral co-pathogen, with the most common co-infection being CPIV and M. cynos [12].

The molecular detection of CPIV in Asia demonstrates similarly significant circulation. A cross-sectional survey of 571 nasal swabs from dogs with respiratory symptoms in Thailand between November 2015 and December 2018 yielded a 5.6% positivity rate by RT-PCR targeting the nucleoprotein (NP) gene, with whole genome characterization revealing close phylogenetic relationships to CPIV-5 strains from China and Korea [8]. In China, a large-scale investigation of 2,492 samples from 22 provinces conducted between 2018 and 2024 reported CPIV as one of the prominent viral pathogens, alongside CPV-2 and CCoV, with the emergence of a distinct phylogenetic clade in the CPIV fusion (F) gene potentially contributing to reduced vaccine efficacy [14]. Most strikingly, a study in Baghdad, Iraq, employing RT-qPCR on 150 dogs (100 sick and 50 apparently healthy) detected CPIV-5 in 51% of sick dogs and 34% of apparently healthy dogs, representing the first molecular confirmation of CPIV-5 circulation in the region [1]. A comparable investigation in Shiraz, Iran, using semi-nested RT-PCR, found CPIV in 20% of dogs with respiratory signs and 13.33% of apparently healthy dogs, with higher occurrence in non-vaccinated and outdoor dogs [7]. These data underscore that CPIV is not merely a pathogen of clinical outbreaks but is endemic at substantial levels even in populations without overt disease.

Asymptomatic Carriage and Reservoir Dynamics

The most epidemiologically significant feature of CPIV infection is the high proportion of subclinical infections and the capacity of apparently healthy dogs to serve as silent reservoirs. The Iraqi study by Waheed and Al-Graibawi (2025) provides compelling quantitative evidence: 34% of apparently healthy dogs, lacking any respiratory signs, tested positive for CPIV-5 by RT-qPCR [1]. This finding is not anomalous. The Iranian study reported that 13.33% of clinically normal dogs harbored the virus [7]. The detection of CPIV in asymptomatic animals has profound implications for disease control, as these dogs can shed virus into the environment and directly infect susceptible conspecifics, thereby maintaining transmission chains within populations where clinical disease may be sporadic or absent.

The reservoir potential of asymptomatic dogs is amplified by the nature of CPIV shedding dynamics. Experimental studies have documented that vaccinated dogs can still shed virus after challenge, albeit at significantly reduced levels. In a pivotal duration-of-immunity study evaluating an oral Bordetella bronchiseptica-CPIV combination vaccine, vaccinated dogs demonstrated a mean nasal shedding of 0.2 log₁₀ FAID₅₀/mL compared to 1.1 log₁₀ FAID₅₀/mL in placebo-vaccinated controls, representing a statistically significant reduction [21]. However, the persistence of any shedding in vaccinated animals indicates that even immunized populations may contribute to environmental contamination. Earlier work by Emery et al. (1976) demonstrated that the presence of neutralizing antibody was significantly associated with decreased respiratory shedding duration; six days after aerosol challenge, 100% of seronegative controls shed virus compared to only 15% of vaccinated dogs, and by day seven, no virus could be recovered from vaccinated animals [23]. This temporal window of shedding is critical for understanding transmission risk in kennel environments.

The concept of an animal species not being the true natural reservoir has been raised by genomic analyses. Rima et al. (2014) performed deep sequencing of 15 PIV5 strains isolated from humans, monkeys, pigs, and dogs across four decades and made the startling observation that some canine and porcine strains harbored mutations in the small hydrophobic (SH) gene, rendering them incapable of producing the SH protein [15]. This finding raised the formal possibility that dogs may not be the natural host for PIV5, but rather a spillover host in which the virus has adapted through mutation. Such a scenario would reshape our understanding of reservoir dynamics, suggesting that an unidentified primary host, potentially another mammalian species, may serve as the ultimate reservoir from which dogs are sporadically or continuously infected. The genetic stability of the PIV5 genome, with only 7.8% of nucleotides variable and an average pairwise difference of 2.1% between strains regardless of host or geographic origin, further supports the hypothesis of a relatively recent cross-species transmission event or a highly conserved host adaptation [15].

Host Range and Zoonotic Considerations

CPIV is not strictly a canine pathogen. The virus, designated as Orthorubulavirus mammalis (formerly parainfluenza virus 5), has been isolated from a diverse array of mammalian species, raising important questions about inter-species transmission and wildlife reservoirs. Complete genome sequencing of a PIV5 variant (strain ZJQ-221) isolated from a lesser panda (Ailurus fulgens) with respiratory disease in a Guangzhou zoo demonstrated a close phylogenetic relationship with a canine-origin strain (1168-1) from South Korea, confirming that this mammal can serve as a natural reservoir and highlighting the need for viral surveillance in zoo animals [11]. Vaccine-induced disease has been documented in a fennec fox (Vulpes zerda) that succumbed to CDV and CAV-2 coinfection following administration of a multivalent modified-live vaccine containing CPIV, demonstrating that non-domestic canids are susceptible to the vaccine strain components [26].

The zoonotic potential of CPIV has been a subject of scientific interest for decades. Chen et al. (2012) detected neutralizing antibodies against PIV5 in 13 out of 45 human serum samples (approximately 29%), with titers lower than those observed in vaccinated dogs, suggesting widespread but low-level human exposure [16]. The virus is classified as a paramyxovirus within the genus Rubulavirus, a group that includes human parainfluenza viruses. Cheng et al. (2023) explicitly describe CPIV as a zoonotic virus that is widely distributed, and the V protein’s role in inhibiting apoptosis and interfering with the interferon response has implications for understanding cross-species transmission [4]. The World Health Organization (WHO) and the World Organisation for Animal Health (WOAH) maintain surveillance frameworks for emerging paramyxoviruses, and the detection of PIV5 in humans underscores the importance of a One Health approach to monitoring this pathogen. The recent development of comprehensive multiplex PCR panels capable of differentiating CPIV from SARS-CoV-2 and other CIRDC pathogens [29] represents a critical advance for both veterinary and public health surveillance.

Transmission Dynamics and Risk Factors

CPIV transmission occurs primarily through direct contact with infected respiratory secretions and via fomites, with the virus exhibiting remarkable environmental stability. The virus is shed in nasal and oropharyngeal secretions, and experimental studies have demonstrated that aerosol challenge effectively establishes infection [9, 21, 23, 28]. The incubation period is typically 3–10 days, and viral shedding can persist for up to 10–14 days post-infection in unvaccinated animals [21]. The role of co-infections in amplifying transmission efficiency is well-documented. The classic study by Wagener et al. (1984) demonstrated that asymptomatic Bordetella bronchiseptica colonization significantly exacerbated the clinical, radiographic, and pulmonary function changes produced by CPIV-2 infection, with co-infected animals developing lobar bronchopneumonia [9]. This synergistic interaction has been confirmed repeatedly; intranasal vaccination with a bivalent CPIV-B. bronchiseptica vaccine reduced the occurrence of clinical tracheobronchitis by 96%, and reduced viral shedding by 99% compared to controls [27]. The European consensus review by Day et al. (2020) affirmed that CPIV remains an important pathogen in CIRDC and that it facilitates co-infection with both viral and bacterial pathogens, particularly B. bronchiseptica and Mycoplasma cynos [17]. The most common co-infection identified in the 2023 New York State diagnostic data was CPIV and M. cynos [12], further emphasizing this synergy.

Several host and environmental factors modulate CPIV transmission. Age is a significant determinant; a serosurvey of 400 Korean dogs conducted from 2019 to 2022 found that CPIV-5 seropositivity increased with age, with overall seropositivity rates of 82.0% [20]. This age-related increase likely reflects cumulative exposure rather than waning immunity. Vaccination status profoundly influences transmission dynamics. The Chinese study of 2,492 samples reported that protective serological rates against CPIV in vaccinated dogs were only 49.0%, considerably lower than the protective rates for CPV-2 (76.9%) and CDV (72.1%), and the emergence of a distinct phylogenetic clade of the CPIV F gene may contribute to this reduced vaccine efficacy [14]. In contrast, the Korean serosurvey found that the protection rate against CPV was 98.3%, while CPIV was substantially lower [20]. The apparent disconnect between vaccination and protection against CPIV highlights the need for ongoing antigenic surveillance and potential vaccine strain updates. Environmental factors such as housing density are critical; the Shiraz study reported higher CPIV occurrence in outdoor dogs and those with contact with other dogs [7], and high-density environments such as shelters and boarding kennels are well-established amplification sites for CPIV transmission [13, 17].

Genomic Stability and Evolutionary Dynamics

Despite its global distribution and diverse host range, CPIV exhibits remarkable genomic stability. The comprehensive comparative genomic analysis by Rima et al. (2014) revealed that strain diversity is exceptionally low, with only 7.8% of nucleotides variable and an average pairwise difference of just 2.1% between strains isolated from different hosts, years, and geographic locations [15]. This stability is maintained even under laboratory conditions of high-multiplicity serial passage in Vero cells, where the genome remained remarkably constant despite competition with defective interfering genomes. The observation that mutations in canine and porcine strains predominantly involve U-to-C transitions suggests an important role for adenosine deaminase, RNA-specific (ADAR)-like activity in generating genetic variation [15]. This mechanism of biased hypermutation may contribute to the loss of SH gene function in certain host lineages, potentially representing a host-specific adaptation. The absence of convincing evidence for positive selection in the hemagglutinin-neuraminidase (HN) gene, despite the presence of neutralizing antibodies in infected hosts, indicates that CPIV may not be under strong immune-driven selection pressure, possibly due to the immunomodulatory effects of the V protein [4, 15]. This genomic stability is a double-edged sword: it suggests that vaccines may retain efficacy over longer periods, but it also implies that the virus is well-adapted to its host and may be difficult to eradicate.

The epidemiological profile of CPIV is thus characterized by high global prevalence, substantial asymptomatic carriage that sustains transmission, a broad host range with zoonotic implications, and a remarkable genomic stability that belies its capacity for widespread circulation. The reservoir dynamics are complex, involving domestic dogs, wildlife such as lesser pandas and fennec foxes, and potentially other mammalian species that may serve as the true natural host. The consistent detection of CPIV as the most prevalent viral agent in CIRDC across multiple continents and over decades of surveillance underscores its status as a pathogen of major clinical and epidemiological importance, demanding continued molecular surveillance, updated vaccination strategies, and enhanced diagnostic capabilities to monitor its evolution and transmission.

Clinical Significance in Canine Infectious Respiratory Disease Complex

Canine parainfluenza virus (CPiV) stands as one of the most clinically consequential pathogens within the etiologically complex syndrome known as the Canine Infectious Respiratory Disease Complex (CIRDC), also widely referred to as kennel cough or infectious tracheobronchitis [2, 13, 17]. Its significance is not merely as a single agent of disease but as a cornerstone pathogen that facilitates, potentiates, and complicates infections by other viral and bacterial agents. The clinical relevance of CPiV spans from its high prevalence in both healthy and diseased populations, its role as a primary initiator of respiratory epithelial damage, its profound capacity for synergistic interactions with bacterial pathogens, and its implications for vaccine strategies and molecular diagnostics. Understanding the nuanced clinical behavior of CPiV within the CIRDC framework is essential for veterinary practitioners, shelter medicine specialists, and researchers seeking to mitigate the substantial morbidity associated with this syndrome.

Prevalence and Primary Etiological Role in Respiratory Disease

The clinical significance of CPiV is underscored by its consistently high detection rates in diverse canine populations globally. A comprehensive five-year retrospective study conducted at a veterinary diagnostic laboratory in Georgia, USA, analyzing 459 CIRDC cases from 2018 to 2022, identified CPiV as the most prevalent viral agent, detected in 16% of all cases. This frequency substantially exceeded that of other viral pathogens, including canine adenovirus type 2 (4%), canine distemper virus (3%), canine respiratory coronavirus (7%), and canine influenza virus (2%) [2]. Similarly, a large-scale Chinese epidemiological investigation spanning 2018 to 2024 across 22 provinces, which tested 2,492 dogs, found CPiV positivity rates that were not strongly associated with vaccination status, suggesting that the virus continues to circulate even in vaccinated populations [14]. This finding is critical because it indicates that current vaccination protocols may not provide sterilizing immunity, thereby maintaining a reservoir of viruses capable of causing clinical disease.

The detection of CPiV in apparently healthy dogs further amplifies its clinical significance. In a study from Baghdad, Iraq, CPiV-5 was detected in 51% of sick dogs exhibiting respiratory distress but also in 34% of apparently healthy dogs, a finding that led investigators to conclude that clinically normal dogs could act as reservoirs, contributing to transmission to susceptible animals and ultimately increasing morbidity [1]. This subclinical carriage is not an isolated phenomenon; an Iranian study reported CPiV infection in 13.33% of healthy dogs and 20% of dogs with respiratory signs [7]. The clinical implication is profound: the virus can persist in a population without causing overt disease in all individuals, creating silent transmission chains that complicate outbreak control, particularly in high-density environments such as shelters, boarding kennels, and breeding facilities [13].

Synergistic Interactions and the Pathogenesis of Coinfections

Perhaps the most critical aspect of CPiV clinical significance lies in its well-documented ability to synergize with other CIRDC pathogens, most notably Bordetella bronchiseptica and Mycoplasma species. The seminal experimental work by Wagener et al. in 1984 established a mechanistic foundation for this synergy. In a controlled study, Beagle pups colonized with B. bronchiseptica prior to CPiV-2 inoculation developed significantly more severe clinical disease, including radiographic changes and reduced pulmonary dynamic compliance, compared to dogs infected with CPiV alone. Importantly, the dual-infected animals developed lobar bronchopneumonia, a finding absent in dogs infected with CPiV only [9]. This interaction is not merely additive but synergistic; the study demonstrated that asymptomatic B. bronchiseptica colonization could fundamentally alter the clinical, radiographic, and pulmonary function consequences of subsequent CPiV infection [9]. This finding has direct clinical relevance for managing dogs in environments where B. bronchiseptica is endemic, dogs with subclinical carriage of the bacterium may be at substantially higher risk of severe respiratory disease upon CPiV exposure.

The clinical synergy extends to Mycoplasma species. A New York State retrospective analysis of 705 canine respiratory PCR panels conducted in 2023 revealed that the most common coinfection pattern was CPiV with Mycoplasma cynos [12]. This finding aligns with data from Georgia, where M. canis (24%) and M. cynos (21%) were among the most prevalent bacterial agents identified alongside CPiV [2]. The clinical significance of this coinfection is substantial; a European review emphasized that M. cynos is significantly associated with more severe respiratory signs and is frequently found together with other CIRDC pathogens, including CPiV [17]. Molecular diagnostic panels developed for CIRDC have consistently identified CPiV as a key component of coinfections, with one study reporting that 30.3% of clinical samples contained multiple pathogens, with CPiV frequently among them [29]. The clinical takeaway is clear: when a clinician identifies CPiV in a respiratory sample, the likelihood of concurrent bacterial infection is high, and this coinfection is associated with greater disease severity.

Molecular Mechanisms of Virulence and Immune Evasion

The clinical behavior of CPiV is inseparable from its molecular biology, particularly the functions of its nonstructural V protein. Cheng et al. (2023) provided an exhaustive review of the V protein's multifaceted roles, highlighting its capacity to inhibit apoptosis, alter the host cell cycle, and interfere with the interferon response [4]. This immune evasion capability is the molecular basis for the virus's ability to establish infection, replicate efficiently, and persist in the face of host defenses. The V protein's inhibition of the interferon pathway allows CPiV to dampen the antiviral state of infected cells, creating a permissive environment for viral replication and, critically, for secondary bacterial colonization [4]. This mechanism directly explains the clinical observation that CPiV infection predisposes dogs to bacterial superinfection, as the virus compromises the innate immune barrier of the respiratory epithelium. Furthermore, the genome stability of CPiV across different hosts and temporal periods, as demonstrated by deep sequencing studies showing an average pairwise difference of only 2.1% between strains, suggests that the virus has evolved highly effective and conserved strategies for immune evasion that do not require extensive antigenic variation [15]. This genetic stability is clinically reassuring from a vaccine development perspective but also indicates that the virus remains a consistently potent pathogen.

Impact on Host Physiology: Beyond the Respiratory Tract

CPiV's clinical significance extends beyond the classic signs of coughing and nasal discharge. A specialized but diagnostically relevant finding is the virus's capacity to induce olfactory dysfunction. Myers et al. (1988) demonstrated that dogs naturally infected with CPiV and those experimentally inoculated with the C958 strain exhibited significantly elevated thresholds for detecting odorants such as benzaldehyde and eugenol. Notably, in experimentally infected dogs, this olfactory deficit developed in the absence of other clinical signs, indicating that anosmia or hyposmia could be an early or even subclinical manifestation of CPiV infection [22]. This finding has significant implications for working dogs, including detection dogs, search-and-rescue animals, and military canines, where olfactory acuity is essential for performance. The olfactory thresholds returned to normal after clinical signs resolved, but the transient dysfunction represents a clinically relevant impairment that may go unrecognized by owners and handlers [22]. The mechanism did not appear to involve histologic damage to the olfactory mucosa, suggesting a functional rather than structural basis for the deficit, potentially mediated by viral interference with olfactory receptor neuron signaling [22].

Diagnostic Challenges and Clinical Decision-Making

The clinical significance of CPiV is further illuminated by the diagnostic challenges it presents. A case report from Italy described a vaccinated household dog presenting with acute, dry paroxysmal cough and retching, initially suspected to have a foreign body due to the afebrile onset. Only through molecular diagnostics on bronchoalveolar lavage fluid was CPiV identified as the sole etiologic agent, with all other CIRDC pathogens testing negative [6]. This case illustrates that CPiV can cause significant respiratory disease even in vaccinated dogs and that its clinical presentation can mimic other conditions. The authors emphasized that molecular diagnostics are fundamental to avoid underestimating the circulation of CPiV in owned dogs, not just in kennel populations [6]. The development of advanced diagnostic tools, including Taqman probe-based multiplex real-time PCR assays capable of simultaneously detecting CPiV alongside CRCoV, CIV, and CDV, has improved the efficiency and accuracy of CIRDC diagnosis [30]. These assays enable clinicians to differentiate CPiV from other viral causes of respiratory disease, which is essential for appropriate case management, prognostication, and implementation of infection control measures. Duplex real-time RT-PCR assays that incorporate a canine endogenous internal positive control (16S rRNA) further enhance diagnostic reliability by minimizing false-negative results, a critical consideration when clinical decisions hinge on test outcomes [3]. The availability of rapid, point-of-care assays such as reverse-transcription loop-mediated isothermal amplification (RT-LAMP) with colorimetric detection, which can be completed in 40 minutes at a constant temperature, has democratized CPiV diagnosis, making it feasible in resource-limited settings [5].

Implications for Vaccination and Population Management

The clinical significance of CPiV is directly addressed through vaccination, yet the relationship between vaccination and disease prevention is nuanced. A Korean serosurvey found that 82.0% of 400 dogs had virus-neutralizing antibodies against CPiV-5, with seropositivity increasing with age [20]. While this indicates widespread exposure, it also underscores that natural infection does not confer lifelong immunity, and vaccination remains critical. The efficacy of CPiV vaccines has been demonstrated in multiple studies. Oral administration of a modified-live B. bronchiseptica-CPiV combination vaccine significantly reduced nasal shedding of CPiV (0.2 log₁₀ FAID₅₀/mL in vaccinated dogs compared to 1.1 log₁₀ FAID₅₀/mL in placebo controls) for at least one year following vaccination, demonstrating that vaccination can mitigate transmission even if it does not completely prevent infection [21]. Intranasal vaccination has shown particularly robust efficacy, reducing the occurrence of clinical tracheobronchitis by 96% and limiting viral shedding to only 1% of observation days compared to 70% in controls [27]. However, the Chinese epidemiological study highlighted a critical challenge: the emergence of a distinct phylogenetic clade of the CPiV F gene may contribute to reduced protective efficacy against CPiV, as only 49% of vaccinated dogs in that survey had protective antibody titers [14]. This finding suggests that antigenic drift may be undermining vaccine effectiveness in some geographic regions, necessitating ongoing surveillance and potential vaccine strain updates. The World Organisation for Animal Health (WOAH) and veterinary authorities globally recognize the importance of respiratory vaccination in kennel environments, and the data support that even vaccines that reduce, rather than eliminate, infection carry substantial epidemiological advantages by reducing shedding and decreasing antimicrobial usage [17].

Public Health and Zoonotic Considerations

While the primary clinical significance of CPiV pertains to canine health, the virus's status as a paramyxovirus with the capacity to infect multiple mammalian species carries implications for public health and interspecies transmission. CPiV, considered synonymous with parainfluenza virus 5 (PIV5), has been isolated from humans, although its role in human disease remains unclear [4, 15]. The remarkably low genomic diversity across strains isolated from humans, dogs, pigs, and monkeys over four decades, with an average pairwise nucleotide difference of only 2.1%, suggests that CPiV/PIV5 may have a broad host range and could potentially be zoonotic [15]. One study detected neutralizing antibodies against PIV5 in approximately 29% of human serum samples, indicating exposure, albeit at lower titers than those observed in vaccinated dogs [16]. The Centers for Disease Control and Prevention (CDC) considers PIV5 a low-risk pathogen for humans, but the potential for adaptation and emergence cannot be dismissed. Clinically, veterinarians working with CPiV-infected dogs should exercise standard hygiene practices, particularly in households with immunocompromised individuals, although current evidence does not suggest that CPiV poses a significant zoonotic threat. The detection of CPiV in a lesser panda with respiratory disease further underscores the virus's ability to cross species barriers, highlighting the need for surveillance in zoo and wildlife settings [11].

Economic and Operational Impact on Canine Facilities

The clinical significance of CPiV extends to the operational and economic burden it places on canine facilities. Shelters, boarding kennels, breeding establishments, and veterinary hospitals experience substantial costs associated with outbreak management, including diagnostic testing, isolation protocols, treatment of secondary bacterial infections, and lost revenue from facility closures [13]. The high prevalence of CPiV in shelter environments, where it is often the most commonly detected viral agent, means that outbreaks are common and can overwhelm resources [2, 17]. The virus's ability to cause disease in vaccinated dogs, albeit typically milder, complicates outbreak control because reliance on vaccination alone is insufficient [14]. Strict biosecurity measures, including ventilation management, disinfection protocols, and cohorting of new arrivals, are essential to prevent CPiV introduction and spread. The development of point-of-care molecular diagnostics, such as the RT-LAMP assay, has reduced the turnaround time for CPiV detection from days to under an hour, enabling rapid implementation of isolation measures and reducing the duration of facility closures [5]. In shelters, where euthanasia decisions for respiratory disease may be influenced by diagnostic uncertainty, rapid and accurate CPiV detection can prevent unnecessary culling and support treatment-based management approaches. The economic impact of CPiV-induced CIRDC is substantial, emphasizing the need for integrated control strategies that combine vaccination, biosecurity, and molecular surveillance.

Molecular Detection Methods: RT-qPCR, Nested PCR, and Phylogenetic Analysis

The accurate and timely identification of canine parainfluenza virus (CPIV) is paramount for understanding its epidemiology, pathogenesis, and the dynamics of co-infections within the canine infectious respiratory disease complex (CIRDC). Given the clinical overlap of CIRDC pathogens, whereby CPIV infections can be indistinguishable from those caused by canine adenovirus type 2 (CAV-2), canine distemper virus (CDV), canine respiratory coronavirus (CRCoV), or Bordetella bronchiseptica, molecular diagnostics provide an indispensable layer of specificity and sensitivity [2, 13, 30]. The methodologies employed have evolved from conventional gel-based techniques to highly sophisticated, multiplexed, quantitative real-time platforms. Among these, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), nested reverse transcription PCR (nRT-PCR), and subsequent phylogenetic analysis represent the cornerstone of contemporary CPIV detection and characterization, enabling not only the diagnosis of active infections but also the molecular epidemiological tracking of viral strains across geographic and temporal scales.

Reverse Transcription-Quantitative PCR (RT-qPCR) Assays

RT-qPCR has become the gold standard for the detection of CPIV RNA due to its high analytical sensitivity, quantitative capacity, and rapid turnaround time. The development of these assays has focused on targeting conserved genomic regions to ensure broad reactivity across circulating strains while avoiding cross-reactivity with other canine respiratory pathogens. Several viral genes have been selected as amplification targets, each offering distinct advantages. The nucleocapsid (NP) gene, the hemagglutinin-neuraminidase (HN) gene, and the large polymerase (L) gene are the most frequently utilized regions [1, 3, 30]. For instance, Zhou et al. developed a TaqMan probe-based multiplex real-time PCR targeting the NP gene of CPIV, achieving a detection limit of 100 copies/μL, which was deemed adequate for clinical application within a CIRDC diagnostic panel [30]. This assay demonstrated superior specificity compared to conventional RT-PCR when analyzing 341 clinical samples, effectively distinguishing CPIV from CRCoV, CIV, and CDV [30].

The choice of target gene can profoundly influence assay performance, particularly in terms of diagnostic sensitivity. Jeon et al. provided a comprehensive comparison of three distinct qRT-PCR assays for CPIV-5: one targeting the HN gene, one targeting the N gene, and a newly developed duplex real-time quantitative RT-PCR (dqRT-PCR) targeting the L gene [3]. The authors demonstrated that the L gene-specific dqRT-PCR assay possessed a sensitivity of less than 10 RNA copies per reaction and 1 TCID₅₀/mL, which was 10-fold higher than the HN gene-specific assay and equivalent to the N gene-specific assay [3]. Critically, when applied to clinical samples, the Ct values obtained with the L gene assay were consistently lower than those from the HN and N gene assays, indicating superior diagnostic performance [3]. This enhanced sensitivity is likely attributable to the higher degree of sequence conservation within the L gene, which encodes the viral RNA-dependent RNA polymerase.

A significant advancement in the field has been the incorporation of internal positive controls (IPC) to monitor for reaction inhibition and nucleic acid extraction efficiency, thereby reducing the risk of false-negative results. The dqRT-PCR assay developed by Jeon et al. exemplifies this, as it simultaneously amplifies the CPIV-5 L gene and a canine endogenous internal positive control (EIPC) based on the 16S rRNA gene [3]. The stable amplification of 16S rRNA in all samples containing canine cellular material provided a robust mechanism for validating negative results and ensuring assay reliability [3]. This duplex approach is particularly valuable for analyzing challenging clinical specimens, such as nasal swabs or broncho-alveolar lavage fluid (BALF), which may contain inhibitors of enzymatic amplification [6].

Multiplexing has been further extended to pan-pathogen panels, enabling the simultaneous detection of multiple CIRDC agents in a single reaction. Comprehensive panels have been developed that include CPIV alongside CDV, CAV-2, CRCoV, CIV, B. bronchiseptica, Mycoplasma cynos, and Mycoplasma canis [29, 31, 32]. These assays utilize distinct fluorophores and optimized primer-probe sets to prevent cross-reactivity and competitive inhibition. For example, Dong et al. validated a three-panel multiplex real-time PCR achieving limits of detection for CPIV RNA templates as low as 2 copies/μL, with PCR amplification efficiencies exceeding 90% and correlation coefficients (R²) above 0.993 for all targets [32]. This level of performance allows for the accurate quantification of viral load, which can be correlated with disease severity and shedding dynamics. The application of such panels in diagnostic laboratories, such as the New York State Animal Health Diagnostic Center, has revealed that CPIV is among the most commonly detected viral agents in canine respiratory cases, frequently co-occurring with M. cynos [12]. The biological relevance of these co-infections cannot be overstated, as CPIV is known to disrupt local mucosal barriers and modulate the host interferon response via its V protein, thereby facilitating secondary bacterial colonization and exacerbating clinical disease [4, 9, 17].

Nested and Semi-Nested Reverse Transcription PCR

While RT-qPCR offers superior sensitivity and quantification, conventional nested RT-PCR (nRT-PCR) retains a critical role in the confirmatory detection of CPIV, particularly for downstream molecular characterization. The nested PCR strategy involves two sequential amplification rounds using two sets of primers, which significantly enhances sensitivity and specificity by reducing non-specific amplification. In their 2025 study, Waheed and Al-Graibawi employed a two-step approach: all samples that screened positive by RT-qPCR were subsequently rechecked using RT-nPCR [1]. This methodology served a dual purpose: it provided confirmatory evidence of true positivity and generated amplicons of sufficient quantity and purity for direct Sanger sequencing. The authors successfully sequenced ten final RT-nPCR products targeting the nucleocapsid protein gene, which were then deposited in the NCBI GenBank database for phylogenetic analysis [1].

Semi-nested RT-PCR, which utilizes one external primer and one internal primer, has also been effectively applied for CPIV detection. Rahmani et al. used this technique to survey dogs in Shiraz, Iran, detecting CPIV in 20% of dogs with respiratory signs and 13.33% of apparently healthy dogs [7]. The semi-nested design offers a balance between the enhanced specificity of a full nested reaction and a reduced risk of carryover contamination, making it a practical choice for epidemiological studies where molecular confirmation and sequencing are required [7]. However, it is essential to note that nRT-PCR is inherently more time-consuming and labor-intensive than RT-qPCR, and it is generally not suited for high-throughput diagnostics. Its primary value lies in archiving genomic material for genetic characterization and phylogenetic studies.

The comparative performance of these methods was highlighted in a study by Kim et al., who evaluated a reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay against conventional RT-PCR (cRT-PCR) and qRT-PCR for CPIV-5 detection [5]. Their results demonstrated that the qRT-PCR and RT-LAMP assays possessed 10-fold higher sensitivity than cRT-PCR, and while the nRT-PCR was not directly compared, the principle holds that the increased amplification cycles inherent in nested formats generally provide sensitivity gains over single-round conventional PCR [5]. Nonetheless, the clinical utility of nRT-PCR is underscored by its ability to detect CPIV when initial RT-qPCR results are equivocal or when attempting to amplify degraded RNA from archival samples.

Phylogenetic Analysis and Molecular Epidemiology

Phylogenetic analysis, rooted in the sequence data derived from RT-qPCR and nRT-PCR amplicons, provides the essential framework for understanding the evolutionary relationships, geographic distribution, and host adaptation of CPIV strains. The analysis relies on bioinformatic algorithms that align nucleotide or amino acid sequences and infer evolutionary trees based on models of molecular evolution. For CPIV, the NP, HN, F, SH, and V/P genes have all been employed for phylogenetic inference, each offering different levels of resolution for epidemiological tracking [1, 8, 14]. The NP gene, in particular, is frequently used for genotyping due to its relatively conserved nature, which facilitates robust alignments across diverse isolates, while the HN and F genes provide greater resolution for distinguishing closely related strains due to their higher mutation rates [8].

Phylogenetic studies have revealed a remarkable degree of genetic stability within CPIV-5, a feature that distinguishes it from other paramyxoviruses like CDV. Rima et al. conducted a deep sequencing analysis of 15 PIV5 strains isolated from humans, monkeys, pigs, and dogs over four decades and found that the overall pairwise sequence divergence was only 2.1%, with just 7.8% of nucleotide positions being variable across the entire genome [15]. This level of conservation suggests that CPIV-5 is under strong purifying selection, possibly due to its adaptation to a broad host range. The study noted that some canine and porcine strains had mutations in the SH gene that ablated its expression, hinting that dogs may not be the natural reservoir for PIV-5, a hypothesis that has implications for transmission dynamics [15].

Despite this overall stability, geographically distinct lineages have been identified. Phylogenetic analysis of Thai CPIV-5 isolates, based on both whole genome sequences and individual HN, F, SH, and V/P genes, demonstrated that Thai strains clustered closely with those from China and Korea, forming an Asian lineage [8]. Conversely, Waheed and Al-Graibawi reported that Iraqi CPIV-5 strains formed two distinct clusters based on amino acid analysis of the NP gene. The first cluster shared high identity with international isolates, while the second cluster diverged significantly, potentially representing indigenous Iraqi strains [1]. This finding underscores the importance of local surveillance, as regional variants may escape immunity induced by vaccines derived from heterologous strains.

The emergence of distinct phylogenetic clades has direct implications for vaccine efficacy. Liu et al. conducted a large-scale molecular survey of canine viral diseases in China from 2018 to 2024 and observed the emergence of a distinct phylogenetic clade of the CPIV F gene [14]. Importantly, their serological survey revealed that the protective rate of vaccinated dogs against CPIV was only 49.0%, significantly lower than the rates for CDV (72.1%) or CAV-2 (85.7%). The authors concluded that the reduced protective efficacy against CPIV might be attributable to antigenic drift within the circulating F gene clade, a concern that parallels the need for periodic updating of human influenza vaccines [14]. This highlights the critical role of continuous phylogenetic monitoring to guide vaccine strain selection and control strategies.

Phylogenetic analysis has also been instrumental in identifying cross-species transmission events. The detection of PIV-5 in a lesser panda with respiratory disease in China, whose genome showed a close relationship to a canine-origin strain from South Korea, suggests that the virus can spill over from domestic dogs into captive wildlife populations [11]. Such findings have conservation significance and stress the necessity of biosecurity measures in zoological settings. Furthermore, the genetic stability of CPIV-5 makes it an attractive candidate for use as a viral vector in vaccine development. Recombinant PIV-5 vectors expressing foreign antigens, such as influenza virus hemagglutinin or rabies virus glycoprotein, have been shown to elicit robust protective immune responses in animal models, and their inherent genetic stability is a key safety advantage [10, 16].

Advances in Multiplex Real-Time PCR for Simultaneous Pathogen Detection

The clinical presentation of canine infectious respiratory disease complex (CIRDC) is notoriously non-specific, characterized by overlapping clinical signs such as paroxysmal dry cough, nasal discharge, and varying degrees of dyspnea, regardless of the etiological agent involved [6, 13, 30]. This syndromic nature, coupled with the frequent occurrence of polymicrobial infections involving both viral and bacterial pathogens, renders syndromic diagnosis unreliable and underscores the critical need for sophisticated, rapid, and comprehensive molecular diagnostic tools [2, 13, 30]. The advent of multiplex real-time polymerase chain reaction (PCR) has fundamentally transformed the diagnostic landscape for CIRDC, shifting the paradigm from single-pathogen detection to high-throughput, simultaneous identification of complex pathogen panels within a single reaction. This technological leap is particularly salient for the detection of canine parainfluenza virus (CPiV), a core and highly prevalent viral component within the CIRDC etiological spectrum [2, 12, 17].

Technological Frameworks for Multiplexing: Probe-Based Strategies and Assay Design

The core innovation in multiplex real-time PCR lies in the strategic deployment of fluorogenic probes, most commonly hydrolysis (TaqMan) probes, which are labeled with distinct, spectrally resolvable reporter dyes. This design permits the concurrent amplification and real-time monitoring of multiple genetic targets within a single closed-tube reaction, dramatically reducing assay time, reagent costs, and the risk of amplicon cross-contamination inherent to conventional, nested, or gel-based multiplex PCR approaches [29, 30]. A landmark study by Zhou et al. (2024) successfully developed a TaqMan probe-based multiplex real-time PCR capable of simultaneously detecting four critical CIRDC RNA viruses: canine respiratory coronavirus (CRCoV), canine influenza virus (CIV), canine distemper virus (CDV), and CPiV [30]. The assay’s design criteria are highly instructive: specific primer-probe sets were meticulously selected to target evolutionarily conserved genomic regions essential for pathogenicity and viral function, including the matrix (M) gene for CRCoV and CIV, the nucleoprotein (N) gene for CDV, and the nucleocapsid protein (NP) gene for CPiV [30]. The analytical sensitivity achieved was robust, with a detection limit of 10 copies/μL for CIV and CRCoV, and 100 copies/μL for CDV and CPiV, demonstrating high reproducibility with both intra- and inter-group coefficients of variation below 2% [30]. This level of precision is critical for reliable quantification and for monitoring viral load dynamics in clinical specimens.

Building upon this foundation, subsequent panels have dramatically expanded the breadth of simultaneous detection. Thieulent et al. (2023) introduced an exceptionally comprehensive panel of four one-step multiplex qPCR/RT-qPCR assays capable of identifying twelve distinct CIRDC pathogens, including CPiV, and further subtyping CIV into H3N2, H3N8, and H1N1 [29]. This panel also incorporated emerging pathogens such as canine pneumovirus and Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), reflecting the need to adapt diagnostic tools to an evolving infectious disease landscape [29]. Similarly, Dong et al. (2022; 2023) validated a nine-pathogen multiplex panel for CIRD that simultaneously detects CPiV, CDV, CIV, CRCoV, canine adenovirus type 2, canine herpesvirus 1, Mycoplasma cynos, Mycoplasma canis, and Bordetella bronchiseptica [31, 32]. Critically, the validation process for such multiplex assays must include rigorous interference testing. Dong et al. demonstrated through spike-in experiments that the presence of high concentrations of one pathogen target did not significantly impede the detection of low-concentration targets within the same reaction, a phenomenon known as competitive inhibition, which is a major potential pitfall in multiplex PCR [31]. The correlation coefficients (R²) for these assays routinely exceed 0.99, and amplification efficiencies fall within the optimal range of 90–108%, confirming the robustness and quantitative accuracy of the multiplex reactions [32].

Enhanced Diagnostic Reliability through Internal Positive Controls

A significant advancement in the sophistication of multiplex assays for CPiV is the integration of an endogenous internal positive control (EIPC) to monitor sample quality, nucleic acid extraction efficiency, and the presence of PCR inhibitors. Jeon et al. (2023) developed a duplex real-time quantitative RT-PCR (dqRT-PCR) assay that simultaneously targets the CPiV L gene and the canine 16S rRNA gene [3]. The L gene, encoding the viral RNA-dependent RNA polymerase, was chosen as the viral target due to its high conservation and sensitivity, outperforming previously established HN and N gene-specific assays [3]. The inclusion of the 16S rRNA EIPC serves a dual purpose: it confirms the presence of amplifiable canine cellular genetic material in the sample, thereby validating the sample adequacy, and it guards against false-negative results that could arise from suboptimal sample collection, degradation of nucleic acids, or reaction inhibition [3]. In the clinical evaluation, the 16S rRNA was stably amplified across all samples containing canine cellular material, and the diagnostic sensitivity of the L gene-specific assay was found to be 10-fold higher than a prior HN-gene assay, detecting as few as ten RNA copies per reaction or 1 TCID₅₀/mL [3]. The calculated Cohen’s kappa coefficient of 1.00 against a reference N-gene assay indicates perfect agreement, confirming the superior diagnostic performance of this duplex approach [3]. This methodological rigor provides a significant advantage over simplex assays or those lacking an EIPC, as it ensures that a negative CPiV result is a true reflection of viral absence rather than a technical failure.

Clinical and Epidemiological Impact of Multiplex Diagnostics

The widespread clinical application of these multiplex panels has fundamentally reshaped our understanding of CPiV epidemiology and its role within the polymicrobial ecosystem of CIRDC. Large-scale retrospective studies employing multiplex PCR panels have consistently identified CPiV as one of the most prevalent viral agents, often exceeding the detection rates of other classic pathogens like CDV and CAV-2 [2, 12, 18]. For instance, a five-year analysis by Yondo et al. (2023) found CPiV in 16% of CIRDC cases, making it the most frequently detected viral pathogen, with prevalence rates fluctuating between 9% and 22% annually [2]. Similarly, a retrospective study from the New York State Animal Health Diagnostic Center reported that the most common co-infection pattern was CPiV with Mycoplasma cynos, highlighting the virus’s frequent role in initiating or facilitating secondary bacterial infections [12]. This is mechanistically plausible, as CPiV is known to cause ciliostasis and disruption of the respiratory epithelium, creating a permissive environment for opportunistic bacterial colonization [9]. Acute clinical cases were significantly more likely to yield positive CPiV results than chronic cases (odds ratio 2.7), and viral agents were more readily detected than bacteria in acute presentations (odds ratio 4.7), underscoring the importance of timely sample collection [12].

The ability of multiplex panels to differentiate between co-infections and single-agent infections has profound implications for therapeutic decision-making and antimicrobial stewardship [17, 29]. The high prevalence of co-infections, often observed in 24-30% of clinical cases [2, 29], militates against the empirical use of broad-spectrum antibiotics, as a purely viral etiology may be the primary driver of disease. The WOAH and CDC recognize the importance of accurate differential diagnosis for respiratory disease in animals to prevent unnecessary antimicrobial use and monitor for emerging zoonotic threats. The inclusion of SARS-CoV-2 in advanced panels is a testament to the One Health approach, enabling surveillance for reverse zoonotic transmission [29]. Furthermore, multiplex PCR has enabled the detection of CPiV in apparently healthy dogs, who can act as subclinical carriers and reservoirs, contributing to the silent transmission of the virus within kennel and shelter environments [1, 7]. Waheed and Al-Graibawi (2025) demonstrated a CPiV-5 detection rate of 34% in clinically healthy dogs, a finding of significant epizootiological importance [1]. This highlights the power of highly sensitive molecular tools to uncover hidden transmission dynamics that would be missed by clinical observation alone.

Biological and Molecular Considerations for Target Gene Selection

The success and reliability of a multiplex assay are fundamentally contingent upon the judicious selection of the viral gene target. For CPiV, several genetic regions have been exploited, each with distinct biological and diagnostic implications. The hemagglutinin-neuraminidase (HN) gene encodes the attachment protein and is a major antigenic determinant, but its variability among strains can sometimes limit the universality of a primer-probe set [3]. The nucleocapsid (NP) gene is highly conserved and is frequently used for diagnostic detection and phylogenetic analysis, as it provides robust sensitivity and specificity [1, 8, 30]. The large (L) polymerase gene, being the most conserved due to its essential enzymatic function, offers a compelling target for pan-detection of CPiV strains, as demonstrated by Jeon et al. (2023) where it provided superior analytical sensitivity compared to an HN-based assay [3]. The choice of target also has implications for the assay's ability to differentiate between wild-type field strains and vaccine strains. Yang et al. (2022) developed a multiplex RT-PCR specifically to differentiate between a Korean CDV wild-type strain and a vaccine strain, a concept that is increasingly relevant for CPiV given the global circulation of distinct genetic lineages [33]. In China, the emergence of a distinct phylogenetic clade of the CPiV F (fusion) gene has been linked to reduced vaccine efficacy, suggesting that multiplex assays must be designed with ongoing viral evolution in mind to ensure they remain capable of detecting all circulating variants [14]. The genetic stability of CPiV/PIV-5 genomes across different hosts and over decades, as revealed by deep sequencing, is reassuring for the long-term utility of primers designed against highly conserved regions like the L gene [15].

Future Directions: Point-of-Care Integration and Isothermal Alternatives

While multiplex real-time PCR remains the gold standard for its high sensitivity and quantitative precision, its dependency on expensive thermal cycling equipment and skilled laboratory personnel can limit deployment in resource-limited settings. To address this, complementary isothermal amplification methods are being explored for point-of-care or field-based diagnostics. A reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for CPiV-5, developed by Kim et al. (2023), offers a rapid (40-minute), equipment-free visual detection method using a hydroxynaphthol blue (HNB) indicator, with a sensitivity of 10 RNA copies/reaction, directly comparable to qRT-PCR and superior to conventional RT-PCR [5]. While isothermal methods are generally single-plex, the field is advancing toward multiplexed colorimetric LAMP by using different pH-sensitive dyes or probe-based LAMP. The integration of these isothermal technologies with multiplexing capability represents the next frontier, potentially allowing for comprehensive CIRDC pathogen panels to be run in a veterinarian’s office without the need for a central laboratory, thereby accelerating the time to diagnosis and enabling more targeted therapeutic interventions. The V protein of CPiV, which plays a crucial role in innate immune evasion by antagonizing interferon signaling [4], also represents a potential target for novel antiviral strategies that could be guided by rapid, multiplex-based diagnosis.

Prevention, Vaccination, and Biosecurity Measures

The strategic mitigation of canine parainfluenza virus (CPIV) within the canine population necessitates a multi-faceted approach that integrates robust vaccination protocols, stringent biosecurity measures, and an understanding of the virus’s epidemiological behavior. As a primary etiological agent of the canine infectious respiratory disease complex (CIRDC), CPIV presents unique challenges due to its high transmissibility, its ability to establish subclinical infections in reservoir hosts, and its frequent synergistic interactions with other respiratory pathogens [1, 2, 13]. The cornerstone of prevention lies in the deployment of effective vaccines, but the ultimate success of any control program hinges on the comprehensive management of the environment and the recognition that vaccination alone may not provide sterilizing immunity.

Vaccination: The Primary Immunological Barrier

Vaccination remains the most critical tool for preventing clinical disease and reducing the circulation of CPIV. The virus is a core component of the widely administered multivalent DAPP (Distemper, Adenovirus, Parvovirus, Parainfluenza) vaccine, which is considered a standard of care in canine preventive medicine [20, 24, 34]. The immunological objective of CPIV vaccination is to induce a robust and durable immune response that can mitigate viral replication in the upper respiratory tract, thereby reducing the severity of clinical signs and curtailing viral shedding.

Vaccine Types and Immunological Mechanisms

Two primary modalities of CPIV vaccines exist: parenteral (injectable) modified-live virus (MLV) vaccines and intranasal (IN) MLV vaccines. The route of administration dictates the nature of the immune response elicited. Parenteral vaccines, typically administered subcutaneously or intramuscularly, are highly effective at inducing systemic humoral immunity, primarily neutralizing antibodies (nAbs) of the IgG isotype [23]. These systemic antibodies are crucial for preventing viremia and severe systemic disease, but their efficacy at the mucosal surface of the upper respiratory tract, the primary site of CPIV replication, is less pronounced. This is a critical distinction, as the virus establishes infection in the ciliated epithelial cells of the trachea and bronchi.

In contrast, intranasal vaccines are designed to stimulate a localized, mucosal immune response. They induce the production of secretory IgA (sIgA) antibodies directly at the portal of entry, providing a first line of defense that can neutralize the virus before it establishes a foothold [27, 28]. Furthermore, IN vaccines are known to stimulate cell-mediated immunity (CMI) more effectively at the mucosal surface. The superior efficacy of IN vaccination in reducing both clinical signs and viral shedding has been well-documented. In a landmark comparative study, dogs vaccinated intranasally with a bivalent CPIV-Bordetella bronchiseptica vaccine exhibited a 96% reduction in the occurrence of clinical tracheobronchitis and a dramatic reduction in viral shedding to only 1% of post-challenge days, compared to 50% in parenterally vaccinated dogs and 70% in unvaccinated controls [27]. This profound reduction in shedding is the single most important factor for population-level control, as it directly interrupts transmission chains. The immunogenicity of IN vaccines is also robust, with studies demonstrating that a single IN dose can induce geometric mean humoral antibody titers comparable to two doses of a parenteral vaccine [27, 28].

Duration of Immunity and Vaccine Efficacy

The duration of immunity (DOI) conferred by CPIV vaccines is a subject of ongoing investigation, but recent evidence supports a minimum of one year. A pivotal study evaluating an oral combination vaccine containing CPIV and B. bronchiseptica demonstrated that a single dose provided significant protection against virulent CPIV challenge for at least 12 months [21]. Vaccinated dogs in this study showed a dramatic reduction in nasal viral shedding (0.2 log₁₀ FAID₅₀/mL) compared to placebo controls (1.1 log₁₀ FAID₅₀/mL), underscoring the vaccine’s ability to limit transmission even in the face of a high-dose challenge [21]. This finding aligns with the established principle that while CPIV vaccines may not always prevent infection entirely, they are exceptionally effective at preventing clinical disease and reducing the infectious period [17, 23].

The efficacy of early vaccination is also a critical consideration for puppy protection. Maternal derived antibodies (MDA) can interfere with vaccine take, creating a window of susceptibility. Recent studies have validated the efficacy of CPIV vaccination in puppies as young as six weeks of age. A study using a DAPPi vaccine (Canigen™ DHPPi) demonstrated that two doses administered two weeks apart, starting at six weeks of age, resulted in a significant reduction in nasal viral shedding after a virulent heterologous CPIV challenge [24]. This early vaccination strategy is vital for closing the immunity gap in high-risk environments like shelters and breeding kennels.

Vaccine Compatibility and Safety

In clinical practice, CPIV vaccines are rarely administered in isolation. They are frequently combined with other core vaccines (e.g., CDV, CAV-2, CPV) and often administered concurrently with rabies vaccine. Rigorous compatibility studies have demonstrated that concurrent administration of a DAPPi-L (Leptospira) vaccine with a monovalent rabies vaccine at separate injection sites does not result in immunological interference for the CPIV component [34, 35]. Non-inferiority analyses confirmed that seroconversion rates and antibody titers against CPIV were equivalent whether the combo vaccine was given alone or with the rabies vaccine [34]. This compatibility is essential for improving vaccination compliance and reducing the number of veterinary visits required.

Safety profiles for MLV CPIV vaccines are excellent. The vaccine virus is attenuated and does not cause clinical disease in healthy dogs. Backpassage studies have failed to demonstrate reversion to virulence, and the vaccine virus cannot be isolated from the blood or nasopharyngeal swabs of vaccinated animals [23]. However, a critical safety caveat exists for non-target species. A case report documented fatal vaccine-induced disease in a fennec fox (Vulpes zerda) following administration of a multivalent MLV vaccine containing CPIV, CDV, and CAV-2 [26]. This highlights the absolute contraindication of using canine MLV vaccines in exotic or wild carnivores without specific safety data, as these species can be highly susceptible to the attenuated vaccine strains.

Biosecurity Measures: Controlling the Environment and Transmission

While vaccination is the cornerstone of individual protection, it is not a panacea. CPIV is highly contagious and can be transmitted via direct contact (aerosolized respiratory droplets), fomites (contaminated bowls, bedding, kennels, and human hands), and even by asymptomatic carriers [1, 7]. Therefore, rigorous biosecurity protocols are indispensable, particularly in high-density populations such as shelters, boarding facilities, and breeding kennels.

Isolation and Quarantine

The cornerstone of biosecurity is the immediate isolation of any dog exhibiting clinical signs of CIRDC, such as a paroxysmal cough, nasal discharge, or retching [6]. Given that CPIV has a short incubation period (typically 3-10 days), any new dog entering a facility should undergo a mandatory quarantine period of at least 10-14 days. This period allows for the manifestation of clinical signs before the animal is introduced to the general population. The detection of CPIV in apparently healthy dogs (34% in one study) underscores the importance of this practice, as these subclinical shedders can act as unwitting reservoirs, perpetuating outbreaks [1]. Facilities should operate on a "all-in, all-out" principle for kennel rotations whenever possible to allow for thorough cleaning and disinfection between groups.

Environmental Disinfection and Fomite Control

CPIV, like other enveloped paramyxoviruses, is relatively susceptible to environmental inactivation by common disinfectants. However, the virus can persist on surfaces for a sufficient duration to facilitate fomite transmission. The use of disinfectants with proven efficacy against enveloped viruses is non-negotiable. Quaternary ammonium compounds, accelerated hydrogen peroxide (AHP), and sodium hypochlorite (bleach) at appropriate dilutions are effective. High-touch surfaces, food and water bowls, kennel doors, leashes, and examination tables, must be disinfected between every animal.

Human hands are a primary vector for pathogen movement. Staff and visitors should adhere to strict hand hygiene protocols, including handwashing with soap and water or using alcohol-based hand sanitizers (containing at least 60% alcohol) before and after handling each animal. The use of dedicated footwear or footbaths containing disinfectant at the entrance and exit of kennel areas is a recommended practice. Furthermore, the use of separate cleaning equipment (e.g., mops, buckets, scrub brushes) for isolation wards versus general population areas is critical to prevent cross-contamination.

Ventilation and Airflow Management

CPIV is primarily transmitted via the aerosol route. In indoor kennel environments, poor ventilation can lead to a high concentration of infectious viral particles in the air, dramatically increasing the risk of transmission. Facilities should be designed to maximize air exchange rates, ideally with a minimum of 10-15 air changes per hour. The use of high-efficiency particulate air (HEPA) filters can further reduce the airborne viral load. Airflow should be directed from clean areas (e.g., isolation wards) toward less critical areas, and recirculation of air should be minimized. Overcrowding is a major risk factor; reducing stocking density directly reduces the viral load in the environment and the frequency of dog-to-dog contact.

Nutritional and Immunomodulatory Support

While not a substitute for vaccination or biosecurity, supporting the host’s innate immune system can contribute to resilience against infection. The nutritional status of the dog directly impacts its ability to mount an effective immune response. Emerging research suggests that certain nutraceuticals may offer adjunctive benefits. For instance, supplementation with Ganoderma lucidum (Reishi mushroom) at a dose of 15 mg/kg body weight has been shown to enhance vaccine-specific serum IgG responses in dogs, suggesting a potential immunomodulatory effect that could bolster the efficacy of CPIV vaccination [36]. Similarly, compounds like deacetylated chitosan, a biopolymer derived from chitin, have demonstrated in vitro antiviral activity against parainfluenza viruses by reducing viral plaque formation and inhibiting virus-induced cellular stress pathways [25]. While these findings are preliminary and require further in vivo validation, they point toward a future where nutritional immunomodulation could be integrated into comprehensive prevention strategies.

The Role of Surveillance and Diagnostics in Prevention

Effective prevention is predicated on accurate and timely diagnosis. The clinical signs of CPIV infection, a dry, hacking cough, are indistinguishable from those caused by other CIRDC pathogens, including Bordetella bronchiseptica, canine adenovirus type 2 (CAV-2), and canine respiratory coronavirus (CRCoV) [6, 30]. Therefore, reliance on clinical diagnosis alone is insufficient and can lead to misdirected control efforts. Advanced molecular diagnostics are essential for confirming the presence of CPIV and differentiating it from co-infecting agents.

The advent of multiplex real-time PCR (qPCR) panels has revolutionized the diagnosis of CIRDC. These assays can simultaneously detect and differentiate CPIV from a panel of other viral and bacterial pathogens in a single reaction, providing a comprehensive etiological picture within hours [29-32]. For example, a validated nine-pathogen panel can detect CPIV alongside Mycoplasma cynos, B. bronchiseptica, and CDV, among others, with high sensitivity and specificity [31, 32]. The use of such panels is critical for identifying the true burden of CPIV in a population and for detecting the high rates of co-infection that are characteristic of CIRDC [2, 12, 18]. Data from diagnostic laboratories consistently show that CPIV is one of the most prevalent viral agents in CIRDC, often found in conjunction with Mycoplasma spp., highlighting the need for a syndromic approach to diagnosis and treatment [2, 12, 13].

Furthermore, the development of rapid, point-of-care diagnostic tools, such as reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assays, offers the potential for on-site detection in resource-limited settings. A visual RT-LAMP assay for CPIV, which can be completed in 40 minutes at a constant temperature and read with the naked eye using a color-changing dye, has demonstrated sensitivity comparable to qPCR [5]. Such tools could empower shelters and field clinics to make real-time biosecurity decisions, such as initiating immediate isolation of a positive animal, without the delay of sending samples to a reference laboratory.

Strategic Implications for Population Management

The ultimate goal of a prevention program is not merely to treat individual cases but to reduce the basic reproductive number (R₀) of CPIV below 1, thereby halting transmission. This requires a population-level perspective. The high prevalence of CPIV in both sick and apparently healthy dogs [1, 7] indicates that the virus is endemic in many regions. Vaccination strategies must achieve high coverage rates to establish herd immunity. The World Organisation for Animal Health (WOAH) and the American Animal Hospital Association (AAHA) guidelines recommend that all dogs, regardless of lifestyle, receive core vaccinations, including CPIV. This is particularly critical for dogs that are boarded, attend daycare, or visit dog parks, as these environments facilitate rapid viral spread.

In shelter environments, where the risk of CIRDC outbreaks is highest, a "universal vaccination upon intake" policy is the gold standard. The use of intranasal vaccines is particularly advantageous in this setting due to their rapid onset of immunity (often within 72 hours) and their ability to induce mucosal immunity that reduces shedding [27, 28]. This rapid protection is invaluable in a shelter where the disease pressure is high and the immune status of incoming animals is unknown. Combining this with strict biosecurity, including cohorting, enhanced ventilation, and rigorous disinfection, creates a multi-layered defense that can effectively suppress outbreaks.

In conclusion, the prevention of CPIV infection is a dynamic process that integrates immunological protection through strategic vaccination with environmental management to interrupt transmission. The development of highly effective, DOI-proven vaccines, particularly those administered intranasally, has provided a powerful tool. However, the persistent circulation of the virus in subclinical carriers and the high frequency of co-infections demand that vaccination be complemented by robust biosecurity protocols, advanced molecular surveillance, and a commitment to population-level health management. Only through this comprehensive, evidence-based approach can the morbidity associated with this ubiquitous pathogen be effectively controlled.

Future Perspectives and Research Directions

The collective body of evidence surrounding canine parainfluenza virus (CPIV), now recognized taxonomically as Orthorubulavirus mammalis (formerly parainfluenza virus 5, PIV5), has matured considerably over the past five decades. Yet, critical gaps in our understanding of its biology, epidemiology, host range, and clinical management persist. As we look toward the next generation of research, several intersecting frontiers demand urgent and sustained investigation. These span from fundamental viral evolution and mechanisms of immune evasion to translational applications in vaccinology, diagnostics, and therapeutics. The following discussion delineates the most pressing research directions, drawing upon the latest molecular, epidemiological, and clinical insights.

### The Enigma of Genetic Stability and Host Tropism: Implications for Emergence

One of the most striking features of CPIV is its remarkable genetic stability across diverse hosts, geographic regions, and decades of isolation. Deep sequencing analyses have revealed that the PIV5 genome displays only 7.8% nucleotide variability across strains, with an average pairwise difference of a mere 2.1% [15]. This stability persists despite the virus circulating in dogs, pigs, non-human primates, and humans, and is evident even after extensive serial passage in cell culture [15]. This presents a fundamental paradox: how does a virus with an RNA-dependent RNA polymerase, typically prone to high mutation rates, maintain such genetic conservation? The observation that biased hypermutation via an adenosine deaminase, RNA-specific (ADAR)-like activity may play a role, particularly in the SH gene of canine and porcine isolates where U-to-C transitions predominate, offers a mechanistic clue [15]. However, the selective pressures, or lack thereof, that maintain this genomic stasis are poorly understood.

Future research must systematically address whether this stability reflects an optimized fitness landscape in a broad range of hosts, or conversely, whether it suggests that dogs are not the primary or natural reservoir. The finding that some canine and porcine strains have lost the ability to encode the SH protein, while primate strains retain it, raises the provocative hypothesis that CPIV may be a human or primate virus that has spilled over into canids [15]. This has profound implications for our understanding of its evolutionary ecology. Rigorous cross-sectional and longitudinal surveillance studies, employing whole-genome sequencing of CPIV isolates from healthy and diseased dogs, cats, wildlife (e.g., the lesser panda [11]), and human populations, are essential. Such work should be coordinated through frameworks advocated by the World Organisation for Animal Health (WOAH) and the World Health Organization (WHO) to monitor for host-switching events and assess zoonotic risk. The detection of neutralizing antibodies in approximately 29% of human serum samples, albeit at low titers [16], underscores the need for ongoing serosurveillance in high-risk populations, including veterinary personnel and immunocompromised individuals, to ascertain whether subclinical human infections are consequential.

### Molecular Epidemiology and the Emergence of Antigenic Variants

While the overall genetic diversity of CPIV is low, phylogenetic analyses have begun to reveal distinct clades with potential epidemiological significance. Studies from Iraq have identified local strains that cluster separately from international isolates, suggesting the circulation of geographically restricted genotypes [1]. Similarly, investigations in Thailand have demonstrated that while Thai CPIV-5 isolates are closely related to those from China and Korea, the full extent of regional diversification remains unknown [8]. Most alarmingly, a large-scale survey in China from 2018 to 2024 detected the emergence of a distinct phylogenetic clade of the CPIV F (fusion) gene, which the authors directly associate with reduced protective efficacy of existing vaccines, noting that only 49% of vaccinated dogs had protective antibody titers against CPIV [14]. This is a critical warning signal for the veterinary community.

Future research must prioritize the establishment of global molecular surveillance networks to track the spatiotemporal dynamics of CPIV lineages. The specific genetic determinants of antigenic drift, particularly in the hemagglutinin-neuraminidase (HN) and F proteins, which are the primary targets of neutralizing antibodies, need to be identified. Reverse genetics systems should be employed to construct recombinant viruses bearing the F and HN genes from emerging field variants and challenge vaccinated animals to directly assess vaccine breakthrough. This is not merely an academic exercise; it is a prerequisite for updating vaccine strains to maintain herd immunity. Furthermore, the role of subclinical shedders, which can constitute 34% of apparently healthy dogs [1, 7], in perpetuating and disseminating novel variants within high-density populations like shelters and boarding kennels must be quantified using high-resolution transmission modeling.

### Next-Generation Diagnostics: From Multiplex Syndromic Panels to Point-of-Care Deployment

The diagnostic landscape for canine infectious respiratory disease complex (CIRDC) has been revolutionized by the development of sophisticated molecular tools. Highly sensitive and specific multiplex real-time PCR assays now allow for the simultaneous detection of up to twelve pathogens, including CPIV, from a single clinical specimen [29-32]. These panels have revealed the true complexity of CIRDC, demonstrating high rates of co-infection, particularly between CPIV and Mycoplasma cynos [2, 12, 13], and have facilitated a shift away from empirical diagnosis. However, significant research and development gaps remain.

First, the translation of these powerful laboratory-based assays to point-of-care (POC) settings is a critical unmet need. The development and validation of a colorimetric reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for CPIV, which provides results within 40 minutes and can be read with the naked eye using hydroxynaphthol blue, represents a major step forward [5]. Future work should focus on integrating such isothermal technologies into multiplex formats that can detect multiple CIRDC pathogens simultaneously. The integration of these POC tools with mobile health platforms for real-time data reporting could transform outbreak response in shelter environments.

Second, the issue of diagnostic sensitivity and specificity for CPIV requires continuous refinement. A duplex real-time quantitative RT-PCR assay targeting the L gene, coupled with a canine 16S rRNA endogenous internal positive control (EIPC), has demonstrated superior diagnostic performance compared to assays targeting the HN or N genes [3]. The EIPC is crucial for preventing false-negative results due to sample degradation or PCR inhibition [3]. Future assay development should universally adopt this strategy. Moreover, the utility of bronchoalveolar lavage fluid (BALF) versus nasopharyngeal swabs for detecting CPIV in cases of lower respiratory tract involvement warrants further investigation, particularly given that cytology can be misleadingly negative even when PCR is positive [6].

### Pathogenesis, Immune Evasion, and the V Protein

The CPIV V protein is a multifunctional non-structural protein that acts as a master regulator of the host antiviral response. It inhibits apoptosis, alters the host cell cycle, and most importantly, potently interferes with the interferon (IFN) signaling pathway, facilitating viral immune escape [4]. This makes the V protein a high-value target for both therapeutic intervention and rational vaccine design. Future research should focus on high-resolution structural studies of the V protein in complex with host cellular targets, such as STAT1 and STAT2, to identify druggable pockets that could be exploited by small-molecule inhibitors. The potential of the V protein in oncolytic virus therapy and as a component of self-amplifying RNA vaccines has been proposed [4], but translational studies in relevant canine models are absent. Specifically, engineering recombinant CPIV with attenuating mutations in the V protein could yield novel, safer, and more immunogenic live-attenuated vaccine candidates. The observation that in vitro antiviral activity of ribavirin against CPIV exists [37] needs to be revisited in the context of modern antiviral screening libraries, potentially targeting the V protein’s interaction with the IFN system.

### Vaccinology: Overcoming Immune Interference and Enhancing Mucosal Immunity

Vaccination remains the cornerstone of CPIV control. The historical efficacy of modified-live intranasal vaccines, which provide superior local IgA and cellular immune responses and reduce viral shedding dramatically compared to parenteral administration [27, 28], is well-established. More recent studies have confirmed that oral vaccination with a combined Bordetella bronchiseptica-CPIV vaccine can confer protection against viral shedding for at least one year [21]. However, several fundamental research questions must be addressed.

The phenomenon of pre-existing immunity to CPIV vector vaccines is a critical area of investigation. While studies have shown that dogs with neutralizing antibodies against PIV5 can still mount a protective immune response to an influenza HA antigen expressed from a PIV5 vector [16], the impact of high-titer maternal antibodies on the efficacy of CPIV-vectored vaccines in young puppies is unknown. The landmark study demonstrating that vaccination can be effective from six weeks of age [24] needs to be expanded to evaluate the precise threshold of maternally derived antibody (MDA) titers that permit successful seroconversion to the CPIV component. Furthermore, the compatibility of CPIV vaccines with other routine immunizations, such as rabies, has been demonstrated [34, 35], but the immunological mechanisms underlying potential non-inferiority issues, such as the observed lower CDV response in one combination [34], should be mechanistically elucidated.

The suboptimal seroprotection rates against CPIV observed in some vaccinated populations (e.g., 49% in China [14] and 82% in Korea [20]) warrant a comprehensive reassessment of correlates of protection. Historically, serological titers have been used as surrogate markers, but these may not accurately reflect mucosal immunity. Future efficacy trials must incorporate standardized challenge models with contemporary, heterologous field strains to establish definitive correlates of protection at both the systemic and mucosal levels. The use of CPIV as a viral vector for vaccines against other pathogens, including influenza, rabies, respiratory syncytial virus, and Mycobacterium tuberculosis, is a highly promising avenue [10]. However, the development of these vectored vaccines must be accompanied by rigorous safety assessments of the construct’s stability and potential for recombination with circulating wild-type viruses.

### The Microbiome, Co-infections, and Antimicrobial Stewardship

The recognition that CPIV is rarely a sole agent but rather acts in concert with other pathogens, particularly Bordetella bronchiseptica and Mycoplasma species, has fundamentally altered our understanding of CIRDC pathogenesis [2, 9, 13, 17]. Experimental co-infection models have demonstrated that asymptomatic B. bronchiseptica colonization synergistically exacerbates clinical signs, radiographic changes, and pulmonary function deficits caused by CPIV infection [9]. The dramatic reduction in bacterial isolation (89%) following intranasal vaccination with a bivalent CPIV-B. bronchiseptica vaccine [27] highlights the potential for viral vaccines to indirectly mitigate bacterial disease.

Future research should employ multi-omic approaches (metagenomics, metatranscriptomics, and metabolomics) to map the ecological dynamics of the canine respiratory microbiome during CPIV infection. Understanding how CPIV disrupts the commensal microbial community and facilitates the overgrowth of pathobionts like M. cynos, which was detected in 66% of canine respiratory panels in one study [12], could identify novel targets for microbiome-sparing therapeutics. This is particularly relevant given the growing threat of antimicrobial resistance. By demonstrating that vaccination reduces viral load and secondary bacterial complications, we can build a strong evidence base for antimicrobial stewardship programs in shelter and kennel settings, potentially reducing the unnecessary use of broad-spectrum antibiotics.

### Novel Antiviral and Immunomodulatory Strategies

The armamentarium against CPIV remains devoid of licensed antiviral drugs. The in vitro activity of ribavirin [37] has not translated into clinical practice, and its toxicity profile is unfavorable. However, recent investigations into natural and biocompatible compounds offer new hope. Deacetylated chitosan, a polysaccharide derived from crustacean shells, has been shown to reduce plaque formation and viral RNA expression of parainfluenza virus type 3 in cell culture, an effect attributed to the suppression of p38 MAPK activation and mitochondrial fragmentation [25]. Similarly, the nutraceutical Ganoderma lucidum has demonstrated immunomodulatory properties in dogs, enhancing vaccine-specific IgG responses [36]. These preliminary findings lay the groundwork for future in vivo studies evaluating the efficacy of such compounds as adjunctive therapies during acute CPIV infection.

High-throughput screening of FDA-approved drug libraries against CPIV in relevant cell lines (e.g., canine respiratory epithelial cells or MDCK cells) is a logical next step to identify repurposing candidates. The unique biology of the paramyxovirus replication cycle, including the RNA-dependent RNA polymerase (L protein) and the hemagglutinin-neuraminidase, provides validated targets for drug discovery. The development of a robust, reverse genetics-based reporter virus expressing a fluorescent or luciferase protein would greatly accelerate these screening efforts.

### One Health Surveillance: The Neglected Interface

Finally, the future of CPIV research must be firmly embedded within a One Health framework. The detection of PIV5 in a lesser panda with respiratory disease [11], combined with the evidence of human exposure [16], underscores the multi-host nature of this virus. There is a glaring absence of systematic surveillance for CPIV/PIV5 in wildlife populations, particularly in canids and felids in zoological collections and free-ranging ecosystems. The use of CPIV-based vaccines in non-domestic carnivores carries inherent risks, as demonstrated by a fatal case of vaccine-induced distemper and adenovirus co-infection in a fennec fox [26]. Research is urgently needed to assess the safety and efficacy of CPIV-vectored vaccines in exotic and endangered carnivores. Simultaneously, the role of human-to-dog or dog-to-human transmission of CPIV, if any, remains entirely uncharacterized. Collaborative efforts between veterinary diagnostic laboratories, public health agencies (e.g., CDC, WHO), and wildlife conservation bodies are essential to close these gaps and ensure that our management of this virus is as sophisticated as our understanding of its molecular biology.

References

[1] Waheed L, Al-Graibawi M. Molecular detection of canine parainfluenza virus-5 in dogs in Baghdad province, Iraq. Open Veterinary Journal. 2025. DOI: https://doi.org/10.5455/OVJ.2025.v15.i6.13

[2] Yondo A, Kalantari A, Fernandez-Marrero I, McKinney A, Naikare HK, Velayudhan B. Predominance of Canine Parainfluenza Virus and Mycoplasma in Canine Infectious Respiratory Disease Complex in Dogs. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12111356

[3] Jeon G, Kim H, Shin Y, Kwon O, Kang H, Kwon O, et al.. An Improved Duplex Real-Time Quantitative RT-PCR Assay with a Canine Endogenous Internal Positive Control for More Sensitive and Reliable Detection of Canine Parainfluenza Virus 5. Veterinary Sciences. 2023. DOI: https://doi.org/10.3390/vetsci10020142

[4] Cheng H, Zhang H, Cai H, Liu M, Wen S, Ren J. Molecular biology of canine parainfluenza virus V protein and its potential applications in tumor immunotherapy. Frontiers in Microbiology. 2023. DOI: https://doi.org/10.3389/fmicb.2023.1282112

[5] Kim J, Kim H, Baek J, Kwon O, Kang H, Shin Y, et al.. Simple and Rapid Colorimetric Detection of Canine Parainfluenza Virus 5 (Orthorubulavirus mammalis) Using a Reverse-Transcription Loop-Mediated Isothermal Amplification Assay. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12070921

[6] Cordisco M, Lucente M, Sposato A, Cardone RA, Pellegrini F, Franchini D, et al.. Canine Parainfluenza Virus Infection in a Dog with Acute Respiratory Disease. Veterinary Sciences. 2022. DOI: https://doi.org/10.3390/vetsci9070346

[7] Rahmani Y, Hasiri M, Mohammadi A. Molecular detection of canine parainfluenza virus circulation among home-owned dogs in Shiraz, Iran.. Bulgarian Journal of Veterinary Medicine. 2016. DOI: https://doi.org/10.15547/BJVM.913

[8] Charoenkul K, Nasamran C, Janetanakit T, Chaiyawong S, Bunpapong N, Boonyapisitsopa S, et al.. Molecular detection and whole genome characterization of Canine Parainfluenza type 5 in Thailand. Scientific Reports. 2021. DOI: https://doi.org/10.1038/s41598-021-83323-9

[9] Wagener JS, Sobonya R, Minnich LL, Taussig LM. Role of canine parainfluenza virus and Bordetella bronchiseptica in kennel cough.. American Journal of Veterinary Research. 1984. DOI: https://doi.org/10.2460/ajvr.1984.45.09.1862

[10] Chen Z. Parainfluenza virus 5–vectored vaccines against human and animal infectious diseases. Reviews in Medical Virology. 2018. DOI: https://doi.org/10.1002/rmv.1965

[11] Zhai J, Zhai S, Lin T, Liu J, Wang H, Li B, et al.. First complete genome sequence of parainfluenza virus 5 isolated from lesser panda. Archives of Virology. 2017. DOI: https://doi.org/10.1007/s00705-017-3245-0

[12] Snedden K, Frye E, Conklin R, Aprea M, Rishniw M, Lejeune M, et al.. A retrospective analysis of canine, feline, and equine respiratory polymerase chain reaction panels performed at the New York State Animal Health Diagnostic Center (January-December 2023).. Journal of the American Veterinary Medical Association. 2025. DOI: https://doi.org/10.2460/javma.24.11.0755

[13] Krstić N, Gnjatović M, Mladjenovic L, Rakin S, Jovanović AA, Nišavić J, et al.. Canine infectious respiratory disease complex (CIRDC) worldwide: A review of epidemiology and distribution. Veterinarski Glasnik. 2025. DOI: https://doi.org/10.2298/vetgl250718015k

[14] Liu C, Chen Y, Cui N, Yang Y, Ding H, Wu H, et al.. Molecular detection of canine viral infectious diseases in China: an investigation from 2018 to 2024. Frontiers in Veterinary Science. 2026. DOI: https://doi.org/10.3389/fvets.2025.1709294

[15] Rima B, Gatherer D, Young D, Norsted H, Randall R, Davison A. Stability of the Parainfluenza Virus 5 Genome Revealed by Deep Sequencing of Strains Isolated from Different Hosts and following Passage in Cell Culture. Journal of Virology. 2014. DOI: https://doi.org/10.1128/JVI.03351-13

[16] Chen Z, Xu P, Salyards GW, Harvey S, Rada B, Fu Z, et al.. Evaluating a Parainfluenza Virus 5-Based Vaccine in a Host with Pre-Existing Immunity against Parainfluenza Virus 5. PLoS ONE. 2012. DOI: https://doi.org/10.1371/journal.pone.0050144

[17] Day MJ, Carey S, Clercx C, Kohn B, Marsilio F, Thiry E, et al.. Aetiology of Canine Infectious Respiratory Disease Complex and Prevalence of its Pathogens in Europe. Journal of Comparative Pathology. 2020. DOI: https://doi.org/10.1016/j.jcpa.2020.02.005

[18] Maboni G, Seguel M, Lorton A, Berghaus R, Sanchez S. Canine infectious respiratory disease: New insights into the etiology and epidemiology of associated pathogens. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0215817

[19] Zaniani AT, Mokhtari A, Esmailnejad A. Molecular and Immunological Investigation of Canine Distemper Virus (CDV) and Its Co- Infection with Canine Parainfluenza Virus Type 2. Iranian Journal of Medical Microbiology. 2021. DOI: https://doi.org/10.30699/IJMM.15.2.212

[20] Yang D, Kim H, Lee H, Cheong Y, Hyun L, Kim M, et al.. Incidence of canine viral diseases and prevalence of virus neutralization antibodies of canine distemper virus, adenovirus type 2, parvovirus, and parainfluenza virus type 5 in Korean dogs. Korean Journal of Veterinary Research. 2024. DOI: https://doi.org/10.14405/kjvr.20230045

[21] Wiechert‐Brown SA, Classe HM, Dant JC, Lafleur R, Xu Z, Tarpey I. One year duration of immunity of a combination Bordetella bronchiseptica - canine parainfluenza oral vaccine in dogs. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1634190

[22] Myers LJ, Nusbaum K, Swango LJ, Hanrahan LN, Sartin E. Dysfunction of sense of smell caused by canine parainfluenza virus infection in dogs.. American Journal of Veterinary Research. 1988. DOI: https://doi.org/10.2460/ajvr.1988.49.02.188

[23] Jb E, Ja H, Jl B, Am S. A canine parainfluenza viral vaccine: immunogenicity and safety.. American Journal of Veterinary Research. 1976. DOI: https://doi.org/10.2460/ajvr.1976.37.11.1323

[24] Loukeri S, Senseby F, Benizeau E, Cronier J, Gueguen S. Efficacy of a Modified-Live Virus Combination Vaccine (CDV, CAV, CPV, CPiV), CanigenTM DHPPi, in Puppies Vaccinated at Six Weeks of Age. Viruses. 2025. DOI: https://doi.org/10.3390/v17121607

[25] Seo DS, Lee JS, Shin YC, Jang Y. Multipotent Antiviral Effects of Deacetylated Chitosan Supplemented with Grapefruit Seed Extract against Influenza and Parainfluenza Viruses. Applied Sciences. 2023. DOI: https://doi.org/10.3390/app13179938

[26] Tamukai K, Minami S, Kurihara R, Shimoda H, Mitsui I, Maeda K, et al.. Molecular evidence for vaccine-induced canine distemper virus and canine adenovirus 2 coinfection in a fennec fox. Journal of Veterinary Diagnostic Investigation. 2020. DOI: https://doi.org/10.1177/1040638720934809

[27] Ej K, Rj W, Ra G. Canine infectious tracheobronchitis: effects of an intranasal live canine parainfluenza-Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough).. American Journal of Veterinary Research. 1981. DOI: https://doi.org/10.2460/ajvr.1981.42.10.1694

[28] Dw C, Jm W, Dl G, Ll H, Fm M. Canine parainfluenza-Bordetella bronchiseptica vaccine immunogenicity.. American Journal of Veterinary Research. 1981. DOI: https://doi.org/10.2460/ajvr.1981.42.02.266

[29] Thieulent CJ, Carossino M, Peak L, Strother K, Wolfson W, Balasuriya UBR. Development and Validation of a Panel of One-Step Four-Plex qPCR/RT-qPCR Assays for Simultaneous Detection of SARS-CoV-2 and Other Pathogens Associated with Canine Infectious Respiratory Disease Complex. Viruses. 2023. DOI: https://doi.org/10.3390/v15091881

[30] Zhou H, Li H, Sun X, Lin J, Zhang C, Zhao J, et al.. Rapid diagnosis of Canine respiratory coronavirus, Canine influenza virus, Canine distemper virus and Canine parainfluenza virus with a Taqman probe-based multiplex real-time PCR.. Journal of Virological Methods. 2024. DOI: https://doi.org/10.1016/j.jviromet.2024.114960

[31] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Validation of a real-time PCR panel for detection and quantification of nine pathogens commonly associated with canine infectious respiratory disease. MethodsX. 2023. DOI: https://doi.org/10.1016/j.mex.2023.102476

[32] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Development of a three-panel multiplex real-time PCR assay for simultaneous detection of nine canine respiratory pathogens.. Journal of Microbiological Methods. 2022. DOI: https://doi.org/10.1016/j.mimet.2022.106528

[33] Yang D, Park Y, Park Y, Hyun B. Establishment of Multiplex RT-PCR for Differentiating between the CD1901 and Lederle Strains of Canine Distemper Virus. Journal of Bacteriology and Virology. 2022. DOI: https://doi.org/10.4167/jbv.2022.52.1.011

[34] Thibault J, Bouvet J, Cupillard L, Cariou C, Oberli F. Compatibility between a rabies vaccine and two canine combined vaccines against canine distemper, adenovirosis, parvovirosis, parainfluenza virus disease and leptospirosis, with or without canine coronavirus. Comparative Immunology, Microbiology & Infectious Diseases. 2022. DOI: https://doi.org/10.1016/j.cimid.2022.101803

[35] Bouvet J, Cariou C, Poulard A, Oberli F, Cupillard L, Guigal P. Compatibility between a rabies vaccine and a combined vaccine against canine distemper, adenovirosis, parvovirosis, parainfluenza virus and leptospirosis.. Veterinary Immunology and Immunopathology. 2018. DOI: https://doi.org/10.1016/j.vetimm.2018.11.001

[36] Kayser E, Osorio LMGM, Godoy MDd. 202 Functional Properties of Ganoderma Lucidum (GL) Supplementation in Canine Nutrition. Journal of Animal Science. 2023. DOI: https://doi.org/10.1093/jas/skad281.130

[37] Rc P. In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus.. American Journal of Veterinary Research. 1978. DOI: https://doi.org/10.2460/ajvr.1978.39.01.175